CGT Research
Biotechnology - secundum medicinae developed et probatus cursim; In annis, biotechnology - secundum pharmaca ingressus in orci tempus ad maxime ieiunium pace, becoming maxime activae agro in pharmaceutical R & d. The development, preclinical research (e.g., drug activity and drug stability), and production these drugs are all dependent on cells, especially for cellular immunotherapies such as stem cell reinfusion, cell exosome reinfusion, chimeric antigen receptor T Cell therapy, tumor-Infiltrating lymphocyte (TIL) therapy, engineered T-cell receptor (TCR) therapy, and natural killer (NK) Cell Lorem. Multi cellulis (ut T Lymphocytes, b lymphocytes, Monocytes, NK cellulis, macrophages, Dendritic cellulis et hepatocytes) non requiritur ad - vitro efficaciam iudicium et productio harum medicinae.
Ideo cellulis et cellula - Related Products habere magna situ in R & D ex nova biotechnology medicinae et Providemus eos in conatibus et investigationis institutions facta est clavis ad promotionem biothnology - secundum medicamento development. Infeliciter, haec products diu fuisse monopolized a paucis amet et posuerunt magna challenges ut summus sumptus, inflexible procuratione, et repugnat uber qualitas.
In responsio ad rei, Iphase praebet cellulis et related products, quae non occurrit in demanda et ostende perficientur comparabiles variis importari faces. Nos proactively Respondeo ad nos mos et providere princeps - qualis officia, imposito solidum fundamentum parallelae substitutio.
Per meSepTM Magna grana copulata cum altus specifica antibody vel antibody universa, T cellulis (CD3 +, CD4 +, CD8 +), B cellulis (CD19 +, CD108 +, cellular cellular cellular. Cellulae non dimisit ex Beads per release quiddam ad downstream cell culturae, fluxus Cytometry Analysis et cellula - secundum assays. Solitaria prima cellulis potest etiam esse gelida usuraIPhasyroTM Quiddam enim diu - terminum repono in liquido nitrogen.